Mainstream

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion

Post ContentalnyRead More

You might also be interested in reading Netflix, other media stocks tumble on Trump’s pledge to hit foreign films with 100% tariff.

February 14, 2025
In Mainstream